Although the level of serum PSA correlates with prostate cancer stage and tumor size, the widespread use of this biomarker has led to the discovery of numerous indolent cancers, which led to the problem of overdiagnosis and overtreatment [25]. This evidence concerns the gene KLK3 and prostate carcinoma.